Trial Profile
Phase II/III trial of WT1 peptide vaccine in patients with multiple myeloma
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 21 Aug 2015
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 19 Aug 2015 Planned initiation date changed from 1 Sep 2015 to 1 Jan 2016 according to a Sellas Life Sciences media release.
- 17 Jan 2015 New trial record